Healthcare / BiotechnologyParis
$2.35
-0.04 (-1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.3M · quality 47.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
23.5x
↑EV/EBITDA
8.4x
↓ROE
3.7%
↑Gross Margin
48.9%
↑Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
—
FCF margin
-58.9%
FCF / Net income
-13.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.0M · net income $927754.0 · FCF $-12.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21.0M | $21.0M | $22.1M | $20.0M | $17.1M |
| Net Income | $927754.00 | $927754.00 | $1.8M | $1.6M | $777752.00 |
| EBITDA | $5.0M | $5.0M | $5.4M | $6.4M | $3.5M |
| EPS | 0.08 | 0.08 | 0.20 | 0.19 | 0.10 |
| Gross Margin | 48.9% | 48.9% | 48.4% | 52.2% | 50.9% |
| Operating Margin | 3.2% | 3.2% | 6.3% | 0.8% | 3.4% |
| Net Margin | 4.4% | 4.4% | 8.3% | 7.8% | 4.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.30 | 0.42 | 0.56 |
| Current Ratio | 8.26 | 8.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.4M | $-12.4M | $3.0M | $1.3M | $438604.00 |
| Returns | |||||
| ROE | 3.7% | 3.7% | 9.9% | 9.0% | 4.8% |
| Valuation | |||||
| P/E | 23.50 | 23.50 | 19.68 | 23.74 | 44.06 |
| EV/EBITDA | 8.39 | 8.39 | 6.81 | 6.28 | 11.02 |
| P/B | 1.14 | 1.14 | 1.94 | 2.13 | 2.12 |
| Growth & Yield | |||||
| Revenue Growth | -5.0% | -5.0% | 10.0% | 17.6% | — |
| EPS Growth | -61.8% | -61.8% | 4.7% | 101.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
39.6%
EPS terminal req.
$0.21
Spread vs growth
-101.4%
5Y implied EPS CAGR
26.9%
EPS terminal req.
$0.25
Spread vs growth
-88.7%
10Y implied EPS CAGR
18.1%
EPS terminal req.
$0.41
Spread vs growth
-79.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.1%
Start / end P/E
17.0x → 30.6x
EPS bridge
0.20 → 0.08
Residual
-49.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.